VitruvianMD, which was founded last year, combines biomedical engineering and cutting-edge artificial intelligence (AI) to provide medical laboratories with inexpensive, high-accuracy diagnostic tools, with a special focus on emerging countries.
“The core of our business is delivering AI-powered diagnostic software into under-resourced areas, and to date, we have built a platform that enables this in various fields of pathology. To further facilitate access, we have also developed a low-cost, high-quality camera that can retrofit any microscope instantly enabling digital telepathology,” said Ifthakaar Shaik, VitruvianMD’s co-founder and chief executive officer (CEO).
“Our platform is robust enough to be utilized in any form of microscopy-based diagnostics, and is proved by our pilots in hematology, histopathology, fertility, and parasitology.”
The Singapore-based Verge Healthtech Fund spearheaded VitruvianMD’s eight-figure ZAR financing round, which also included a number of angel investors. It will be used to help the firm speed the development of its technology and fund the launch of further pilots.
“With this funding, the goal is to reach commercialization of at least one of our diagnostic modules within the next 18 months,” Shaik said.
